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Abstract 
One strategy employed by bacterial strains to resist β-lactam antibiotics is the expression of metallo-β-
lactamases requiring Zn
2+
 for activity. In the last few years, many new zinc β-lactamases have been described 
and several pathogens are now known to synthesize members of this class. Metallo-β-lactamases are especially 
worrisome due to: (1) their broad activity profiles that encompass most β-lactam antibiotics, including the 
carbapenems; (2) potential for horizontal transference; and (3) the absence of clinically useful inhibitors. On the 
basis of the known sequences, three different lineages, identified as subclasses Bl, B2, and B3 have been 
characterized. The three-dimensional structure of at least one metallo-β-lactamase of each subclass has been 
solved. These very similar 3D structures are characterized by the presence of an αββα-fold. 
In addition to metallo-β-lactamases which cleave the amide bond of the β-lactam ring, the metallo-β-lactamase 
superfamily includes enzymes which hydrolyze thiol-ester, phos-phodiester and sulfuric ester bonds as well as 
oxydoreductases. Most of the 6000 members of this superfamily share five conserved motifs, the most 
characteristic being the His116-X-His118-X-Asp120-His121 signature. They all exhibit an αββα-fold, similar to 
that found in the structure of zinc β-lactamases. Many members of this superfamily are involved in mRNA 
maturation and DNA reparation. This fact suggests the hypothesis that metallo-β-lactamases may be the result of 
divergent evolution starting from an ancestral protein which did not have a β-lactamase activity. 
Keywords: Bacterial resistance ; class B β-lactamases ; zinc binding sites ; αββα-fold ; conserved motifs ; 
metallo-β-lactamase superfamily 
Abbreviations: MBL, metallo-β-lactamase; BBL, class B β-lactamase; ISCR, insertion sequences common 
regions 
 
1.        β-Lactams 
The β-lactam antibiotics comprise six different structural subtypes, including penams, cephems, monobactams, 
cla-vams, penems, and carbapenems. The penams include benzylpenicillin and ampicillin. The cephems include 
classical cephalosporins such as cephaloridine, nitrocefm, and cefotaxime, as well as cephamycins, which are     
7-α-methoxy-cephalosporins. The monobactams are monocyclic β-lactams and include aztreonam. The penems 
have a 2, 3-double bond in the fused thiazolidine ring (hence dihydrothiazole), similar to the carbapenems (e.g. 
imipenem, biapenem), which also have an unsaturated fused five membered ring, with carbon in place of sulfur 
at the 1-position. 
2.        Metallo-β-lactamases 
β-Lactamases are the major cause of resistance of bacteria to β-lactam antibiotics. These enzymes cleave the 
amide bond of the β-lactam ring thus inactivating the antibiotic, β-Lactamases fall into four classes. Classes A, C 
and D are serine-β-lactamases which employ an active-site serine to catalyze hydrolysis, while metallo-β-
lactamases or class B β-lactamases are metallo-enzymes requiring one or two zinc ions for their activity. 
Metallo-β-lactamases can degrade all classes of β-lactams except monobactams and are special for their constant 
and efficient carbapenemase activity. This is a most worrisome characteristic because carbapenems, which are 
stable against the vast majority of serine-β-lactamases produced by resistant pathogens, are the antibiotics with 
the broadest spectrum of activity. Moreover, metallo-β-lactamases are not susceptible to therapeutic                         
β-lactamase inhibitors. Thefirst of these enzymes, the Bacillus cereus metallo-β-lactamase, was identified in 
1966 when Sabbath and Abraham showed that the cephalosporinase activity produced by a B. cereus isolate was 
inhibited by EDTA [1]. During the two following decades, it was the only known example of metallo-β-
lactamase and was merely considered as a biochemical curiosity. The situation changed after 1980. Indeed, zinc 
β-lactamases have been discovered in an increasing number of nosocomial strains such as Bacteroides fragilis 
[2], Pseudomonas aeruginosa [3], Aeromonas hydrophila [4], Serratia marcescens [5], Elizabethkingia 
meningoseptica (formely Chryseobacterium meningosepticum) [6] and a silent gene coding for a metallo-β-
lactamase was discovered in Bacillus anthracis [7]. The emergence and dissemination of acquired metallo-β-
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lactamases, encoded by genes carried on mobile DNA elements, among major Gram-negative pathogens, 
including members of the family Enterobacteriaceae, P. aeruginosa, and Acinetobacter species made the 
situation even more worrying [8]. Moreover, many metallo-β-lactamase genes are present in environmental 
species which thus constitute reservoirs of β-lactam resistance genes [9-12]. Metallo-β-lactamases are now 
regarded as a therapeutic challenge and the comprehension of their frightening properties is necessary in the fight 
to overcome them. 
 
Table 1 - Metallo-β-lactamases 







Bl BcII B. cereus 1966 M11189 AAA22276 Mono-zinc [48],  
      Di-zinc [50] 
      Apo-form [50] 
 CcrA B. fragilis 1990 M63556 AAA22904 Di-zinc [49] 
 BlaB E. meningoseptica 1998 AF189298 008498 Di-zinc [52] 
 IND-1 Chryseobacterium 
indologenes 
1999 EF394437 AB021411  
 EBR-1 E. breυis 2002 AF416700 AAN32638  
 SFB-1 Shewαnellα frigidimarina 2005 AY590119 AAT90847  
 SLB-1 Shewαnellα 
livingstonensis 
2005 AY590118 AAT90846  
Acquired-
B1 







 VIM-1 P. aeruginosa, A. 
baumannii 
1999 Y18050 CAE46717  
 VIM-2 P. aeruginosa, A. 
baumannii 
2000 AF191564 AAK26253 Mono-zinc 1K02,  
      Di-zinc 1K03 
 IMP-2 A. baumannii, S. 
marcescens 
2000 AB182996 BAD26594  
 SPM-1 P. aeruginosa 2002 AY341249 AAR15341 Mono-zinc [53] 
 VIM-4 P. aeruginosa, K. 
pneumoniae, 
Enterobacter cloacae 
2003 AY135661 AAR22402  
 GIM-1 P. aeruginosa 2004 AJ620678 CAF05908  
 SIM-1 A. baumannii 2005 AY887066 AAX76774  
B2 CphA A. hydrophila 1991 X57102 P26918 Mono-zinc [36] 
 ImiS Aeromonas veronii 1996 Y01415 CAA71411  
 Sfh-1 S. fonticola 2003 AF197943 AAF09244  
B3 L1 Stenotrophomonas 
maltophilia 
1991 AB294542 CAB75346 Di-zinc [22],  
      Mono-zinc 
2H6A, 
      Apo-form 2FU6 
 GOB-1 E. meningoseptica 2000 AF090141 AB021417  
 FEZ-1 L. gormanii 2000 Y17896 CAB96921 Di-zinc [54] 
 THIN-B J. lividum 2001 AJ250876 CAC33832  
 Mbl1b C. crescentus 2001 AJ315850 CAC48262  
 CAU-1 Caulobacter vibrioides 2002 AJ308331 CAC87665  
 BJP-1 B. japonicum 2006  NP_772870 Di-zinc 2GMN 
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Table 2 - Minimal Inhibitory Concentrations (µg/ml) for E.coli strains producing some metallo-β-lactamases 












































Amoxicillin 2 128 >512 512 16 >512 64 - - - - - 
Amoxicillin-
CLA 
2 - >512 512 16 512 - - - - - - 
Ticarcillin 2 256 >512 512 16 > 512 64 - - - 4 >128 
Piperacillin 1 4 8 4 1 4 2 1 16 1 1 1 
Cephalothin 2 16 32 8 4 256 32 4 - 32 4 >128 
Cefuroxime 4 - 128 32 2 - - 4 - 32 4 >128 
Ceftazidime 0.06 - 0.5 32 0.12 16 - 0.12 256 0.5 0.12 32 
Cefotaxime 0.06 0.12 0.5 0.5 0.12 8 0.25 0.06 - 4 <0.06 32 
Cefepime 0.06 0.03 0.12 0.06 0.06 0.06 0.06 0.06 4 - <0.06 2 
Cefpirome 0.06 0.06 0.12 - - - 0.5 - - - - - 
Ceftriaxone 0.06 - 0.25 - - - - 0.125 128 - <0.06 32 
Cefoxitine 4 2 8 4 4 128 16 2 - 32 2 >128 
Moxalactam 0.12 0.12 1 0.06 0.06 - 1 - - - - - 
Aztreonam 0.12 0.25 0.12 0.06 0.12 0.12 0.25 0.12 0.125 0.12 0.25 0.25 
Imipenem 0.06 0.5 0.5 0.5 0.25 1 0.5 0.12 0.5 0.25 0.12 1 
Meropenem 0.06 0.12 0.25 0.12 0.25 0.25 0.12 0.03 0.125 0.25 <0.06 2 
 [15] [20] [15] [25] [25] [40] [20] [21] [41] [21] [42] [42] 
-, not determined. 
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3.        Classification 
The class B β-lactamases are classified into three subclasses Bl, B2 and B3 on the basis of sequence alignments 
[13]. The classification task was complicated by the generally low degree of similarity between subclass 
sequences but facilitated by the availability of X-ray structures (see below), which allowed the identification of 
corresponding secondary structures elements, even when the sequence similarity was not obvious. The standard 
BBL numbering of class B β-lactamases allows easy comparisons of the sequences of these enzymes [13]. 
Subclass B1 enzymes share more than 23% identity. These enzymes include the prototypical BcII from B. cereus 
[14], CcrA from B. fragilis [2], BlaB from E. meningoseptica [6] and EBR-1 from Empedobacter breυis [15]. 
The acquired IMP-type MBLs found in some clinical isolates of P. aeruginosa [16], S. marcescens [5], 
Klebsiella pneumoniae (GenBank EMBL accession no D29636) and Acinetobacter baumannii [8], as the VIM-
type or SPM-1 enzymes produced by clinical isolates of P. aeruginosa [8,17], belong also to this subclass (Table 
1). 
The members of subclass B2 show only 11% of identity with subclass Bl members. This subclass includes the 
enzymes produced by different species of Aeromonas (the most studied are CphA produced by A. hydrophila [4] 
and ImiS produced by A. veronii [18]) as well as the Sfh-I enzyme produced by Serratia fonticola [9] (Table 1). 
Subclass B3 metallo-β-lactamases have only nine conserved residues when compared with the other metallo-β-
lactamases. Subclass B3 includes the L1 and GOB-1 metallo-β-lactamases produced by clinical strains of          
S. maltophilia [19] and E. meningoseptica (formely C. meningosepticum) [20] and FEZ-1 isolated from 
Legionnella gormanii [21]. To date, 18 variants of GOB-1 have been reported, but none outside the E. 
meningoseptica species. In GOB enzymes, His116 is replaced by a glutamine. THIN-B [10], Mbl1b [11], and 
BJP-1 [12] produced by environmental bacteria (Janthinobacter lividum, Caulobacter crescentus and 
Bradyrhizobium japonicum, respectively) belong also to this subclass (Table 1). With the exception of L1 which 
is a homo-tetramer [22], all these enzymes are monomeric as are the B1 and B2 enzymes. 
 
4.         MICs 
Compared to the reference Escherichia coli strains, strains producing a metallo-β-lactamase exhibit decreased 
susceptibility to a broad array of β-lactam antibiotics, including penicillins, narrow- and expanded-spectrum 
cephalospor-ins, and carbapenems (Table 2), indicating that metallo-β-lactamases have a broad overall substrate 
specificity profile. Only the MICs of aztreonam are unchanged, suggesting that theses enzymes are not active 
against this compound. It has also been observed that E. coli expressing the cphA gene is resistant only to 
carbapenems and only when high inocula (10
8
 CFU) are used for MIC determinations [23]. However, a rational 
approach of the correlation between the MICs and the kinetic parameters of the β-lactamase is made difficult by 
the absence of knowledge of outer membrane permeability for many of the usually studied β-lactam antibiotics 
and by the fact that most authors do not estimate the amount of enzyme produced. 
5.         Activity profiles 
The metallo-β-lactamases belonging to subclasses B1 and B3 are broad spectrum enzymes and hydrolyze most 
β-lactam antibiotics including carbapenems [24] (Table 3). Only the monobactams are neither hydrolyzed nor 
recognized by these enzymes which are not inhibited by classical inhibitors of serine-active β-lactamases such as 
clavulanic acid and tazobactam. These compounds in fact behave as poor substrates. SFB-1 from the 
psychrophilic Shewanella frigidi-maria is an unusual subclass Bl β-lactamase which does not significantly 
hydrolyze benzylpenicillin, ticarcillin, third generation cephalosporins and meropenem [25]. 
The subclass B2 enzymes are strict carbapenemases [18,23,24]. They only hydrolyze carbapenems efficiently 
and show a very weak activity, if any, towards penicillins and cephalosporins (Table 3). In B2 enzymes, the 
conserved His116 of B1 and B3 enzymes, is replaced by an asparagine. The presence of this asparagine in 
position 116 is far from being the only reason which explains the narrow spectrum of B2 metallo-β-lactamases, 
since, although increased, the activity of the N116H CphA mutant towards penicillins and cephalosporins 
remains low [26]. A mutant of CphA with a considerably broadened activity spectrum, N116H-N220G, was 
recently obtained by site-directed mutagenesis [27]. In contrast to the wild-type enzyme, it is able to efficiently 
hydrolyze penicillins and cephalosporins in addition to carbapenems although with a reduced efficiency towards 
the latter (Table 3). 
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 Table 3 - Kinetics parameters of some metallo-β-lactamases 






































Bell 680 1500 4.5 × 10
5
 45 70 6.4 × 10
5
 >100 >1000 1 × 10
5
 [24] 
CcrA 190 40 4.8 × 10
6
 200 20 1 × 10
7
 200 270 7.4 × 10
5
 [24] 
EBR-1 120 50 2.4 × 10
6
 - - - 190 780 2.4 × 10
5
 [15] 
BlaB 280 30 9 × 10
6
 20 70 2.8 × 10
5




IMP-1 320 520 6.2 × 10
5
 60 30 2 × 10
6
 50 40 1.2 × 10
6
 [16] 
VIM-1 30 840 3.5 × 10
4
 100 20 5 × 10
6
 2 2 1 × 10
6
 [8] 
VIM-2 60 50 1.2 × 10
6
 - - - 10 10 1 × 10
6
 [8] 
SPM-1 110 40 2.8 × 10
6
 0.50 4 1.2 × 10
5
 30 40 7.5 × 10
5
 [53] 
GIM-1 7 50 1.4 × 10
5
 6 10 6 × 10
5




CphA 0.03 870 35 0.003 1200 2.5 1200 340 3.5 × 10
6
 [26] 
CphA     N116H 0.4 910 440 0.09 30 3 × 10
3
 150 1400 1.1 × 10
5
 [26] 
CphA     N116H-
N220G 
3 150 2 × 10
4
 0.7 4 1.8 × 10
5
 20 190 1 × 10
5
 [27] 
ImiS 0.50 250 2 × 10
3
 0.06 20 3 × 10
3




LI 1100 50 2 × 10
7
 20 10 2 × 10
6
 65 90 7.2 × 10
5
 [24] 
FEZ-1 70 590 1.2 × 10
5
 90 100 9 × 10
5
 >200 >1000 2 × 10
5
 [88] 
GOB-1 200 110 1.8 × 10
6
 - - - 40 60 6.6 × 10
5
 [20] 
Mbllb 770 20 3.8 × 10
7
 1800 100 1.8 × 10
7
 940 200 4.7 × 10
6
 [11] 
-, not determined. 
 
6.         Phylogeny 
Subclasses B1 and B2 are descended from a common ancestor and really form a single group within which the 
sequences exhibit significant similarities, with subclasses Bl and B2 forming two distinct clades within the 
group. Subclass B3 shares structural but not sequence similarities with the B1/B2 group [28]. A phylogenetic 
tree with representative members of all the three subclass is given in the previous Ref. [28]. Hall and Barlow 
have proposed, on this basis, to revise the classification of metallo-β-lactamases [29]. However, the presently 
accepted classification reflects other properties of these enzymes. Functional and mechanistic factors clearly 
distinguish the B1, B2 and B3 enzymes from each other and, on this basis, B2 is not more related to Bl than B3 
(see activity profile, zinc coordination points). Thus it seems unnecessary to modify the broadly accepted 
nomenclature [30]. 
7.         Catalytic mechanism 
Bounaga et al. (1998) [31] have proposed a mechanism for the monozinc form of the subclass B1 BcII enzyme. 
In this mechanism, the zinc ion interacts with His116, His118, His196 and a water molecule. The zinc ion 
behaves as a Lewis acid and decreases the pK of the water molecule so that it exists as a hydroxide ion at neutral 
pH. This ion performs a nucleophilic attack on the carbon of the carboxyl group of the β-lactam, leading to the 
formation of a tetrahedral intermediate stabilized by its interaction with the zinc ion. Asp120, acting as a general 
base, deprotonates the -OH group to generate a dianionic tetrahedral second intermediate which is also stabilized 
by the zinc ion. In a subsequent step, Asp120 gives the proton to the nitrogen of the β-lactam ring and takes part 
in cycle opening. 
A mechanism based on the study of the hydrolysis of nitrocefin (a chromogenic cephalosporin) by the CcrA and 
L1 enzymes has been proposed for the dizinc form of metallo-β-lactamases. A ring-opened intermediate 
containing an anionic nitrogen was identified, the protonation of which was rate-limiting [32-34]. But the 
mechanism observed for nitrocefin seems to be atypical, due to its highly conjugated bis-nitro-substituted styryl 
substituent which is ideally suited to stabilize the negatively charged nitrogen. When other substrates are used, 
the cleavage of the tetrahedral intermediate, which occurs concomitantly to the protonation of the nitrogen of the 
β-lactam ring, appears to be the rate-limiting step [35]. 
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A different reaction mechanism has been proposed for the monozinc subclass B2 enzymes [36,37]. The 
nucleophilic hydroxyde is generated by the Aspl20 and His118 residues. This nucleophile attacks the β-lactam 
carbonyl, possibly activated by His196, to generate a tetrahedral intermediate. As observed for Bl and B3 
enzymes, the rate-limiting step in the reaction is the C-N bond cleavage. The crystal structure of CphA shows the 
presence of a bicyclic product of biapenem in the active site of the enzyme [36]. Garau et al. proposed that, after 
β-lactam bond cleavage, a substantial bond rotation occurs that allows the nucleophilic attack of C3 by the 
oxygen of the 6-hydroxyethyl substituent with concomitant transfer of its proton to C2. This cyclization occurs 
after C-N bond cleavage. Some results indicate that the final product of imipenem hydrolysis by ImiS is different 
from that by L1 but the NMR spectra of both products are the same [37]. 
A very recent study of D120N, D120E, D120Q and D120S BcII mutants indicates that Asp120 is not the proton 
donor, nor does it play an essential role in nucleophilic activation. It is proposed that the role of Asp120 is to act 
as a strong Zn2 ligand, locating this ion optimally for substrate binding, stabilization of the development of a 
partial negative charge in the β-lactam nitrogen, and protonation of this atom by a zinc-bound water molecule 
[38]. 
8.        Genetic organization 
Some members of subclass B1 are encoded by the chromosome such as BcII from B. cereus [14] and BlaB from 
E. meningoseptica [6]. The gene coding for CcrA (B. fragilis) is often quiescent and requires a surrogate 
sequence to provide an adequate promoter. Insertion elements, such as IS942, IS1186 and IS4351, have been 
shown to lie immediately upstream of the ribosome-binding site, providing enhanced transcriptional capabilities 
for the CcrA gene [39]. 
 
Fig. 1 - Current spread of acquired metallo-β-lactamases. Data are obtained from Ref. [8] and from the 17th 
European Congress of Clinical Microbiology and Infectious Diseases, 25th International Congress of 
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Five plasmid-borne sets of transferable B1 metallo-β-lactamase genes have presently been identified of which 
the IMP- and VIM-types occur most frequently (Table 1). The IMP-type enzymes, produced by P. aeruginosa 
[16], S. marcescens [5], K. pneumoniae (GenBank accession no. D29636), have now spread worldwide [8] (Fig. 
1). The VIM-type enzymes, produced by P. aeruginosa and Acinetobacter, appear as the most prevalent in 
Europe with more than 12 allelic variants [8] (Fig. 1). The other foci for the VIM-enzymes appear to be East 
Asia and Americas [8] (Fig. 1). VIM-2, first discovered in France (Marseille) in 2000 [40], is currently the most 
widespread acquired MBL. It was found repeatedly in Western (Belgium, Germany, Greece, Italy, Portugal, 
Spain) and Eastern Europe (Croatia, Poland, Russia), United States, Latin America and Asia (China, India, 
Japan, Korea, Taiwan). Three other types of acquired metallo-β-lactamases, SPM-1, GIM-1 and SIM-1, have 
been found in South America [17], Germany [41] and Korea [42] (Fig. 1) which suggests that the capture by 
bacteria of similar resistance genes in the clinical setting could be an ongoing, relatively common, and rapidly 
increasing phenomenon. These enzymes are produced by P. aeruginosa (SPM-1, GIM-1) and A. baumannii 
(SIM-1). 
The transferable metallo-β-lactamases are commonly encoded by genes carried by type 1 or type 3 integrons [8]. 
These integrons could be carried by large plasmids or be located on the chromosome. The MBL blaSPM-1 is not 
part of a gene cassette, nor is it found in the vicinity of a class 1 integron as found for other metallo-β-lactamase 
genes, but it is located besides the ISCR variant ISCR4 [8-43]. ISCR (IS common regions), a new type of genetic 
element, was recently identified as being closely associated with the spread of many antibiotic resistance genes. 
They can be divided into two groups: ISCRs1 are those that form complex class 1 integrons and ISCRs-2 to -13 
are those associated with non-class 1 integrons. ISCRs are also associated with Salmonella enterica serovar 
Typhimurium pathogenecity islands. ISCR elements are very unusual in that they can mobilize large sections of 
adjacent DNA via a rolling circle replication. Normally, termination of replication occurs at a defined site; 
misreading of this site leads to replication of large sections of DNA to the left-hand end of the element including 
antibiotic resistance genes. Using a PCR strategy employing degenerate primers designed against the aligned 
DNA sequences of ISCRsl to -5, Toleman has detected ISCR elements in several strains of P. aeruginosa and A. 
baumannii that harbor metallo-β-lactamase genes e.g. ISCR2 was discovered in a P. aeruginosa isolate (Brazil) 
that harbored blaIMP-1 and ISCR3 was discovered in two strains of P. aeruginosa (Italy) that have blaVIM-1 [43]. 
The genes coding for subclass B2 enzymes are located on the chromosome and their expression can be regulated 
by the presence of β-lactam antibiotics in the culture medium via a two-components BlrAB system [44]. 
Subclass B3 metallo-β-lactamases are generally chromosome encoded. The gene coding for L1 could be located 
on the chromosome or on a large plasmid [45]. The production of this β-lactamase is induced by the presence of 
β-lactam antibiotics in the medium. 
Most natural producers of class B enzymes also produce class A β-lactamases, as do B. cereus [46], S. 
maltophilia [45], or class D enzymes as does L. gormanii [47]. Several Aeromonas species produce a class C and 
a class D β-lactamases in a co-regulated way with the metallo-β-lactamase [44]. 
9.        Structures 
The three-dimensional structure of the mono-zinc form of BcII was the first to be solved [48]. Thereafter, the 
structures of other subclass B1 enzymes, CcrA [49], the di-zinc form of BcII [50] (Fig. 2a), IMP-1 [51], BlaB 
[52], VIM-2 (PDB accession no. 1K02 and 1K03), SPM-1 [53] (Fig. 2b), and subclass B3 enzymes, LI [22] 
(PDB accession no. 2H6A), FEZ-1 [54] (Fig. 2d) and BJP-1 (PDB accession no. 2GMN), were determined. 
More recently, the structure of a subclass B2 enzyme, CphA, was solved [36] (Fig. 2c). Despite of the low level 
of identity between the amino acid sequences, the general fold of these enzymes is similar and consists of an 
αββα structure, composed by two central β-sheets with five solvent-exposed α-helices. The N-terminal and C-
terminal parts of the molecule, each of them comprising a β-strand and two α helices, can be superposed by a 
180° rotation around a central axis, suggesting that the complete structure might have arisen from the duplication 
of a gene [48]. In all known structures, the active site is located at the external edge of the ββ sandwich. 
The N-terminal domain of B1 metallo-β-lactamases incorporates a loop (residues 61-65) that can interact with 
substrate or inhibitor molecules which possess hydrophobic side-chains (Fig. 2a). This loop is very flexible in 
the native form of the enzyme. When the substrate or the inhibitor diffuses into the active site, the loop moves to 
block the molecule in the active site. This movement of the loop is caused by the interaction of the side chain of 
the W64 residue with the hydrophobic side chain of the substrate [55]. The loop is also stabilized upon binding 
of inhibitors [51,52] and transforms the active site groove into a tunnel-shaped cavity. The deletion of this loop 
(named flap) seriously affects the enzymatic activity by weakening the binding of substrate to the enzyme, with 
the exception of imipenem [55]. Actually, the kinetic parameters of this carbapenem compound are barely 
affected by the absence of the active site loop. The main difference between the carbapenems and other β-
lactams is that both penicillins and cephalosporins usually have bulky aromatic ring substitutions which are 
absent in the former. 
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Fig. 2 - Metallo-β-lactamases overall structures. The helices are represented in blue, strands in green and loops 
in grey, (a) Subclass Bl Bell enzyme with the mobile 61-65 loop in magenta, (b) Subclass Bl SPM-1 enzyme with 
residues 61-65 in magenta and the extended α3-α4 region in orange, (c) Subclass B2 CphA enzyme with the 
elongated α3 helix in orange, (d) Subclass B3 FEZ-1 enzyme with the 151-166 loop in red. (e) Representation of 
the zinc binding sites of subclass Bl (Bell), B2 (CphA), and B3 (Fez-1) β-lactamases. 
 
 
The 61-65 flap is absent in β-lactamases of subclasses B2 and B3. 
The subclass B2 CphA metallo-β-lactamase possesses an elongated α3 helix (residues Arg140-Leu161) close to 
the active site groove (Fig. 2c). This helix presents a kink about Trp150 that enables α3 to follow the surface 
curvature of the protein and provides a hydrophobic face that contributes to the binding of carbapenem substrates 
[36]. Consequently, CphA exhibits a very well defined active site, which explains the very narrow activity 
profile of the enzyme. 
The structure of the subclass Bl SPM-1 enzyme shows that it lacks the 61-65 mobile loop. In SPM-1, strands β3 
and β4 are separated only by a stretch of five amino acid residues that form a tight turn. Moreover, SPM-1 
accommodates a central insertion of 24 amino acids in an extended α3-α4 region (residues 150b-165) (Fig. 2b). 
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Deleting this insertion has only marginal effects upon binding and hydrolysis of a range of β-lactam antibiotics 
[53]. Both structural features of SPM-1 are reminiscent of that found in the subclass B2 CphA enzyme. By these 
aspects, SPM-1 thus represents a structural hybrid between subclasses Bl and B2. Moreover, when the sequence 
of SPM-1 is compared to that of other metallo-β-lactamases, the highest identities are seen with IMP-1 (35.5%) 
and then the subclass B2 enzymes ImiS (32.2%) and CphA (32.1%). 
In subclass B3 enzymes, a loop between α3 and β7 formed by residues 151-166 is mobile and close to the active 
site [22,54] (Fig. 2d). The I166A mutant of L1 exhibited increased Km values only when cefoxitin was the 
substrate, suggesting an interaction of the isoleucine side chain with the cefoxitin methoxy group. The F160A 
mutant of L1 exhibited higher Km values when using the cephalosporins as substrates, suggesting an interaction 
of the cephalosporins' substituents with the phenylalanine on the loop that extends over the active site [56]. L1 is 
a tetramer, a characteristic unique among β-lactamases. One main interaction between two subunits involves the 
extended N-terminal region [22]. L1 also contains a disulphide bridge in its monomer and a similar one can be 
seen in the structure of FEZ-1 [22,54], whereas this is no intramolecular disulphide bridge in the enzymes of 
subclasses B1 or B2. 
10.        Zinc coordination 
Metallo-β-lactamases possess two potential Zn2+ binding sites (Fig. 2e). In the case of Bl enzymes, one zinc ion 
possesses a tetrahedral coordination sphere and is coordinated by His116, His118, His196 and a water molecule 
or OFT ion. The other metal ion has a trigonal-pyramidal coordination sphere which involves Asp120, Cys221, 
His263 and two water molecules (Table 4). One water/hydroxide molecule serves as a ligand for both metal ions. 
The two binding sites are named the "histidine" and "cysteine" sites, respectively. In the mono-nuclear BcII, 
VIM-2 and SPM-1 enzymes, the sole metal ion was shown to be located in the "histidine" site [48,PDB 
accession no. 1KO2, 53]. 
 
 Table 4 - Composition of the two metal binding sites in the MBL superfamily 
Daiyasu's groups Enzymes Site 1 Site 2 
Group 1 B1 MβLs His116-His118-His196 Asp120-Cys221-His263 
Group 1 B2 MβLs Asp120-Cys221-His263 His118?-Met146? or His196? 
Group 1 B3 MβLs His116-His118-His196 Asp120-His121-His263 
Group 1 B3 MβL GOB Asp120-His121-His263 ? 
Group 2 Glyoxalase II His116-His118-His196-Asp221 Asp120-His121-Asp221-His263 
Group 3 ROO His116-Glu118-His196-Asp221 Asp120-Asp221-His263 
Group 3 FprA His116-Glu118-His196-Asp221 Asp120-His121-Asp221-His263 
Group 4 tRNaseZ, ZiPD His116-Glu118-His196-Asp221 Asp120-His121-Asp221-His263 
Groups 6 and 7 CPSF-73 His116-Glu118-His196-Asp221 Asp120-His121-Asp221-His(C) 
Group 9 Pce His116-His118-Asn196-Asp221 Asp120-His121-Asp221-His263 
Group 12 AiiA lactonase His116-Glu118-His196-Asp221 Asp120-His121-Asp221-His263 
Group 13 SdsA1 His116-His118-Glu196 Asp120-His121-Glu221-His263 
Group 15 MPH His116-His118-His196-Asp221 Asp120-His121-Asp221-His263 
 
In the B3 enzymes, the "histidine" site is the same as that found in Bl enzymes. Cys221 is replaced by a serine 
and the second zinc ion is ligated by Asp120, His121, His263 and the nucleophilic water molecule which forms 
a bridge between the two metal ions (Table 4). Ser221 does not directly interact with the zinc ion but with a 
second water molecule located in the active site and which could serve as proton donor in the catalytic process 
[22]. In contrast to all other related metallo-β-lactamases, the subclass B3 GOB-18 enzyme is fully active against 
a broad range of β-lactam substrates as a mono-zinc species. Different spectroscopic techniques, 3D modeling, 
and mutagenesis experiments, reveal that the zinc ion is bound to Asp120, His121, His263, and a solvent 
molecule, i.e., in the canonical site 2 of dinuclear B3 metallo-β-lactamases [57] (Table 4). However, L. Horsfall 
found two zinc ions per GOB-1 molecule after a purification procedure during which no Zn
2+ 
was added to the 
buffers [89]. These two GOB enzymes differ by a few point mutations, apparently far from the active site 
(Leu94Phe, Ala137Val and Asp282Asn). 
While the B1 and B3 enzymes exhibit maximum activity as di-zinc species, the B2 β-lactamases are inhibited in 
a non-competitive manner upon binding of a second Zn
2+
 ion (for CphA, the dissociation constant Ki is 46 µM at 
pH 6.5 [58]). In agreement with EXAFS spectroscopy studies [59] and site-directed mutagenesis [26], the 
crystallographic structure of CphA shows that the first zinc ion is in the "cysteine" site [36]. Currently, the 
identification of the second binding site in subclass B2 enzymes remains unsettled since even in the presence of 
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a large excess of zinc (10 mM) and in spite of the low value of the dissociation constant, Garau and his 
coworkers did not succeed in obtaining crystals of the di-zinc form. On the basis of spectroscopic studies with 
the cobalt-substituted ImiS enzyme, Crawford et al. postulate that in subclass B2 the second metal binding site is 
not the traditional "histidine" site [60]. Costello et al. propose that in ImiS the inhibitory zinc ion binds to both 
His118 and Met146 [61]. Indeed, their EXAFS data show that the inhibitory zinc is bound by a sulfur. The sulfur 
ligand in the inhibitory site should come from a methionine residue, since the only cysteine residue (Cys221) is a 
ligand of Zn1. The mutation of Met146 to lie abolishes inhibition by zinc. However, mutations of other CphA 
residues, which have not been implicated as Zn2 ligands, can have similar effects (lower inhibition or even 
activation by excess of zinc) [26,27]. Moreover, a careful examination of the CphA 3D structure indicates that 
His118 and Met146 are poorly positioned to bind the same zinc ion. The distance between their Cα's is 7.57 Å, 
while the distances between the sulphur of Metl46 and the nitrogens of the imidazole group of His118 are 10.40 
and 10.91 Å, respectively. Also, the space between these residues is occupied and does not allow the 
accommodation of a zinc ion. The Met146 residue is not conserved in the subclass B2 Sfh-I enzyme where it is 
replaced by a glutamine. Maybe, as proposed by Vanhove et al., the Cys221 side-chain is displaced upon binding 
of the second metal ion [26]. The role of His118 residue in the catalytic mechanism [36,37] could explain the 
inhibition by the binding of the second zinc ion, this residue being prevented from playing this role when it is 
immobilized as ligand of this second zinc ion in the di-zinc form of the enzyme. 
11.        Zinc affinities 
The subclass B2 CphA enzyme exists mainly in the mono-zinc form as the values of the dissociation constants 
are 20 nM and 46 µM, respectively for the binding of the first and the second zinc ion [58]. Subclass Bl metallo-
β-lactamases show distinct stereochemical similarities in their active sites, with identical residues contributing to 
metal coordination. However, the corresponding zinc affinities appear to be different, so that CcrA and IMP-1 
show two high-affinity metal-binding sites, whereas BcII binds Znl and Zn2 with very different affinities. 
Fluorescence spectroscopy studies with a chromophoric chelator show that BcII has very different dissociation 
constants for the two metal-binding sites. For the loss of metal-ion from the mononuclear enzyme, the 
dissociation constant, Kmono, is 6.2 x 10
-10
 M and that for the loss of one metal-ion from the dinuclear MBL, Kdi, 
is 1.5 x 10
-6
M [62]. Kmono decreases significantly, from nanomolar to picomolar values, in the presence of 
substrate, whereas Kdi decreases only twofold [63]. This suggests that the mono-zinc enzyme is responsible for 
the catalytic activity under physiological conditions, where the concentration of free zinc ions is in the picomolar 
range [63]. A single Zn
2+
 ion is found by crystallographic methods in the "histidine" site, at pH 5.6, in presence 
of 100 µM zinc [48]. At this pH, the activity is only three- to fourfold lower than that at pH 7.5 [31]. But the 
existence of the mononuclear form, where the sole metal ion would be shared between the two binding sites is 
supported by several kinetic results, PAC (Cd) and spectroscopic (Co) data [62]. However, one cannot 
completely reject the hypothesis of a strong positive cooperativity between the two zinc ions with coexistence of 
only the apo- and di-zinc forms. At least, Damblon and his coworkers observe that the inhibitor thiomandelic 
acid induces positive cooperativity in metal binding [64]. 
Conversely, and despite the very close similarity with BcII, the class B1 enzyme CcrA binds both zinc ions very 
tightly. Kinetic studies of CcrA with nitrocefin have shown that only the di-nuclear species is active and that a 
previously observed mono-zinc CcrA enzyme [65] was a mixture of the di-zinc and the apo-enzyme [33]. 
BcII is active in the presence of either one or two zinc ions, although full activity is observed when two zinc ions 
are bound. It has been proposed that the arginine 121 present in BcII, Vim-2, BlaB and in subclass B2 enzymes 
is responsible for the lower affinities. The CcrA and IMP-1 enzymes, showing high affinity for both zinc ions, 
have cysteine and serine, respectively, in the corresponding position. The replacement of the positive Arg121 
side chain in CphA by a neutral one enhances the affinity for Zn
2+
 [27], as was already suggested for BcII 
[48,49]. Rasia and Vila [66] have shown that the R121H mutation increases the affinity for the second Zn
2+
 ion 
in BcII and that the His121 side chain replaces that of His263 as a ligand of the second Zn
2+
. The C121R mutant 
of CcrA was isolated in the di-zinc form, although the removal of the second zinc appeared to be facilitated [33]. 
All these data indicate that the replacement of Arg121 by a neutral residue (a Cys, Ser or His, respectively) in 
CcrA, IMP-1, and the subclass B3 enzymes increases the affinity for the second zinc. Until recently, no mono-
zinc form of subclass B3 enzymes has ever been obtained. However, the subclass B3 GOB-18 was shown to be a 
mononuclear enzyme [57]. In the subclass B1 SPM-1 enzyme, a neutral Gly121 is present and, however, SPM-1 
possesses two metal sites of very different affinities [53], thus the presence of Argl21 in BcII is surely not the 
only reason explaining the weaker affinity for Zn2. 
As shown by the data described above, the activity and even the existence of mono-zinc forms of B1 and B3 
enzymes remain controversial. As yet, it seems impossible to supply a clear answer to these questions and it 
remains possible that minor sequence differences might result in different behaviours. For B2 enzymes, the 
mono-zinc form is clearly the active one, but here the location of the inhibitory second zinc remains mysterious 
(although this is probably biologically unrelevant). 
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12.         Inhibitors of metallo-β-lactamases 
All known inhibitors or inactivators of serine β-lactamases are inefficient towards metallo-β-lactamases. 
Reported inactivators of all metallo-β-lactamases are the metal chelators EDTA, o-1, 10-phenanthroline and 
dipicolinic acid, however these have no clinical significance. 
The propagation of metallo-β-lactamases among nosocomial bacterial strains justifies the search for compounds 
which can thwart the activity of these enzymes. Unfortunately, the discovery of a clinically useful, specific 
inhibitor of metallo-β-lactamases is made difficult by the fact that this compound must remain inactive towards 
the human proteins which are members of the metallo-β-lactamase superfamily, or other metallo-enzymes such 
as the angiotensin converting enzyme. Another difficulty is to find a compound active on all the three subclasses 
of metallo-β-lactamases and even on all the enzymes within a same subclass. Currently, the known inhibitors 
efficiently inhibit one or two metallo-β-lactamases and are much less active against the others. Moreover, they 
remain impractical to use as therapeutic agents. In 2004, Toney and Moloughney reviewed the literature on 
inhibitors of MBLs [67], and more recently Walsh et al. devoted a paragraph on experimental inhibitors in their 
review on transferable MBLs [8]. A few examples are thioesters derivatives, trifluoromethyl alcohols and 
ketones, sulfonyl hydra-zones, tricyclic natural products, succinic acid derivatives, biphenyl tetrazoles, cysteinyl 
peptides, carbapenem and penicillin derivatives among which an interesting thiol-substituted penicillin inhibitor 
[68], degradation products of cephalosporins, simple thiol compounds such as mercaptoa-cetic acid and 
thioesters, thiomandelic acid [64], captopril [52,59], derivatives of benzohydroxamic acid [69], pyridine 
carboxylates [70]. 
13.         The metallo-β-lactamases (MBL) superfamily 
The MBL superfamily was defined by Neuwald et al. in 1997 [71]. In addition to metallo-β-lactamases, it 
includes enzymes which hydrolyze thiol-ester, phosphodiester and sulfuric ester bonds as well as 
oxydoreductases. 
Most of the 6000 members of this superfamily share five conserved motifs [72]: Asp84, His116-X-His118-X-
Asp120-His121, His196, Asp221 and His263 (in the order to facilitate comparison, the BBL numbering [13] is 
applied to the MBL superfamily and used throughout this chapter). The fold of these proteins or of one of their 
domains is of the αββα type, similar to the structure of zinc β-lactamases. Almost all these proteins exhibit a 
binuclear metal center similar to that of metallo-β-lactamases. These centers occupy topologically similar 
locations. Among the conserved motifs, Asp84 exhibits a strained secondary conformation and may play a role 
in maintaining the protein fold. The other conserved residues are involved in metal coordination. For the 
majority of these enzymes, the first metal ion binding site is composed of His116, His118 and His 196, while the 
second binding site is composed of Asp120, His121 and His263. A major difference with true metallo-β-
lactamases consists in the presence of an aspartate (Asp221) in the position where a cysteine (B1) or a serine 
(B3) is found in β-lactamases. Asp221 and a water molecule bridge the two metallic ions. 
A large number of hypothetic enzymes found in GenBank could also share this fold and bind one or two metal 
ions, but the majority of these proteins have not been functionally or structurally characterized yet. Daiyasu has 
classified these proteins in 17 families on the basis of their biological functions [72]. Until recently, only three of 
the 17 protein groups proposed to contain this fold had been characterized structurally, true metallo-β-lactamases 
(group 1-see above), glyoxylases II (group 2), and rubredoxin oxidoreductases (group 3). However, more recent 
crystal structures of other family members include acid phosphorylcholine esterase Pce (group 9), the methyl 
parathion hydrolase (group 15), the N-acyl homoserine lactone hydrolase (group 12), the alkylsulfa-tase from P. 
aeruginosa SdsA1 (group 13), the tRNA3'-processing endoribonuclease tRNaseZ (group 4) and proteins 
members of the β-CASP family (groups 6 and 7) (Fig. 3). The composition of both metal binding sites of these 
MBL superfamily enzymes of known structures is described in Table 4. 
13.1.       Group 2 
Glyoxalase II belongs to the glyoxalase system (formed by glyoxalases I and II) which catalyzes the conversion 
of toxic 2-oxoaldehydes to 2-hydroxycarboxylic acids using glutathione as coenzyme. Glutathione thiolesters 
formed in the reactions catalyzed by glyoxalase I are substrates for glyoxalase II and are hydrolyzed by the latter 
enzyme to the free 2-hydroxyacids and gluthathione. Glyoxalase II has been isolated from numerous mammalian 
tissues and from higher plants. The structure of human glyoxalase II is composed of two domains: a metallo-β-
lactamase domain and a smaller α-helical domain (Fig. 3a). It binds 1.5 moles of zinc per mole of enzyme and 
0.7 mole of iron per mole of enzyme [73]. The cytosolic glyoxalase II from Arabidopsis thaliana possesses a 
binuclear center able to bind zinc, iron or manganese and some results indicate that glyoxalase II exhibits 
positive cooperativity in metal binding [74]. The two metal-binding sites present the classical structural features 
of the MBL superfamily (Table 4). 
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Park et al. succeeded in introducing metallo-β-lactamase activity in the αββα scaffold of glyoxalase II by 
simultaneous incorporation and adjustement of functional elements in conjunction with directed evolution [75]. 




) does not 
explain the increased MICs of the producing cells which served as a selection tool, unless unrealistic periplasmic 
concentrations of enzyme are assumed. Moreover, the engineered protein only hydrolyzes cefotaxime and no 
other cephalosporins or penicillins, a very unlikely property for a β-lactamase. 
 
Fig. 3 - Metallo-β-lactamases superfamily overall structures. The metallo-β-lactamase like domains are 
represented in blue (helices), green (strands) and grey (loops and disordered regions). Zinc ions are represented 
as grey spheres and iron ions as beige spheres. (a) Glyoxalase II with the additional α-helical domain in violet. 
(b) ROO with the additional flavodoxin-like domain in violet. (c) phosphorylcholine esterase (Pce) domain of the 
virulence factor choline-binding protein E with the elongated loop lying on the top of the active site represented 
in yellow. (d) N-acyl homoserine lactone hydrolase. (e) MPH monomer. (f) SdsA1 monomer with the additional 
central dimerization domain in pink and C-terminal domain in violet. (g) ZiPD monomer with the 50 amino 
acids exosite in salmon. (h) TTHA0252 with the β-CASP domain in hotpink. 
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13.2.       Group 3 
The metallo-β-lactamase fold is also found in a distinct group of cytosolic redox proteins. Rubredoxin:oxygen 
oxydoreduc-tase (ROO) from Desulfovibrio gigas consists of two domains: a β-lactamase domain and a 
flavodoxin-like domain (Fig. 3b). ROO is not a zinc-enzyme but contains a di-iron center for dioxygen reduction 
[76]. The second histidine in the usual H-X-H-X-DH motif is replaced by a glutamate (Glu118). One iron ion is 
ligated by two histidines (His116, His196), one glutamate (Glu118) and one aspartate (Asp221) while the second 
iron ion is coordinated by one histidine (His263) and two aspartates (Asp120, Asp221). His121, although 
present, does not bind Fe2 [76] (Table 4). A comparison of the ROO structure with that of true metallo-β-
lactamases shows that the L1 β-lactamase is more similar to the first domain of ROO than to other β-lactamases 
[28], and FEZ-1 is closer to glyoxalase II and ROO than to BcII or CphA [13]. 
The structure of FprA from Moorella thermoacetica, which likely functions as a scavenging nitric oxide 
reductase, has also been solved [77]. As in the case of D. gigas ROO, FprA contains a solvent-bridged non-
heme, non-sulfur di-iron site with five-coordinate iron centers bridged by an aspartate, and terminal glutamate, 
aspartate, and histidine ligands. However, in contrast to ROO, the FprA di-iron site exhibits four His ligands, 
two for each iron (Table 4). 
13.3.        Group 9 
The crystal structure of a virulence factor, the phosphorylcho-line esterase (Pce) domain of the choline-binding 
protein E from Streptococcus pneumoniae was solved in 2005 [78]. This domain catalyzes the hydrolysis of 
choline-phosphoester bonds, releasing phosphorylcholine molecules from cell wall-associated teichoic and 
lipoteichoic acids. A striking feature of Pce, unique among the reported structures of the metallo-β-lactamase 
superfamily proteins, is the presence of an elongated loop, which lies on the top of the active site (Fig. 3c). This 
loop would play a role in determining the accessibility of the catalytic cavity for the substrate. Iron ions are 
essential for catalysis. Site 1 comprises His116, His118, Asn196 and Asp221 residues and site 2 Asp120, 
His121, Asp221 and His263 (Table 4). A water/hydroxide molecule bridge completes the coordination spheres 
of the two metals. 
13.4.        Group 15 
The methyl parathion hydrolase (MPH) from Pseudomonas sp. WBC-3 catalyzes the degradation of the 
organophosphate pesticide methyl parathion. MPH is a homodimer, each monomer presenting a typical metallo-
β-lactamase fold [79] (Fig. 3e). MPH possesses a binuclear di-zinc center. The coordination sphere of the zinc 
ions is the same as that found in glyoxalase II (Table 4). 
13.5.        Group 12 
The N-acyl homoserine lactone hydrolase from Bacillus thuringensis is a quorum-quenching lactonase. More 
than 50 species of Gram-negative bacteria, P. aeruginosa for example, are known to use N-acyl-L-homoserine 
lactones (AHLs) as signal-molecules for intercellular "quorum sensing" communication pathways necessary to 
their pathogenicity. Because of their importance in pathogenicity, these pathways are possible targets in the 
development of new therapeutic molecules. Nature has already developed several methods to counter these 
pathways among which the production of quorum-quenching enzymes which hydrolyze the lactone residue of 
AHLs. Their amino acid sequences exhibit the conserved MBL motifs. The quorum-quenching lactonase AiiA 
from B. thuringensis binds two zinc ions and its activity is Zn dependent. The recently solved 3D structure of 
this enzyme [80] highlights the typical αββα-fold (Fig. 3d). The coordination sphere of the zinc ions is the same 
as that found in glyoxalase II (Table 4). 
13.6.        Group 13 
P. aeruginosa is able to degrade and metabolize SDS which is usually a biocide. SdsA1 of P. aeruginosa is a 
secreted SDS hydrolase that allows the bacterium to use primary sulfates such as SDS as sole carbon or sulfur 
sources. The crystal structure of SdsA1 reveals three distinct domains. The N-terminal catalytic domain with a 
binuclear Zn
2+
 cluster is a distinct member of the metallo-β-lactamase fold superfamily, the central dimerization 
domain ensures resistance to high concentrations of SDS, whereas the C-terminal domain provides a 
hydrophobic groove, presumably to recruit long aliphatic substrates (Fig. 3f) [81]. Zn1 is coordinated by His116, 
His118, and Glu896. Asp221 is replaced by a glutamic acid residue. Zn2 is coordinated by His821, His263, 
Asp820 and Glu221. A water molecule bridges the two zinc ions (Table 4). 
13.7.        Group 4 
The crystal structures of Thermotoga maritima tRNaseZ [82], Bacillus subtilis tRNA maturase tRNaseZ [83] and 
E. coli tRNase Z (ZiPD) [84] (Fig. 3g) have been determined. tRNaseZ belongs to the ELAC1/ELAC2 family 
within the MBL superfamily. It is found in the vast majority of, if not all, eukaryotes and archea, and in about 
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half of the sequenced bacterial genomes. Two ElaC variants were recently associated with prostate cancer in 
man. The structure of B. subtilis tRNaseZ is characterized by a long flexible arm extending from the core β-
lactamase domain, this arm permits RNA recognition and hydrolysis of phosphodiester bonds. The E.coli 
homolog of tRNaseZ, ZiPD, also possesses a specific sequence insertion module of ~50 amino acids, referred to 
by the authors as "ZiPD exosite", located between the zinc ligands His196 and Asp221. This exosite is not 
required for phosphodiesterase activity but is essential for pre-tRNA processing and tRNA binding. ZiPD is 
capable of binding two zinc or two iron ions. However, it displays phosphodiesterase activity only in the zinc 
form. The coordination sphere of the zinc ions is the same as that found in glyoxalase II (Table 4). 
13.8.        Groups 6 and 7 
A separate family of enzymes within those exhibiting the metallo-β-lactamase fold, the β-CASP family, 
comprises several important proteins acting on nucleic acid substrates, involved in DNA repair (Artemis, Apollo, 
SNM1 and PS02) and RNA processing (cleavage and polyadenylation specificity factor subunits CPSF-73 and 
CPSF-100) [85]. Two regions can be defined within the protein sequence: the MBL domain and a region specific 
to members of the MBL superfamily acting on nucleic acids. This region is named the β-CASP motif (metallo-β-
lactamases-associated CPSF Artemis SNM1 PSO2). β-CASP family proteins are characterized by three 
conserved sequence motifs [A (Asp or Glu), B (His) and C (His)], following the four typical metallo-β-lactamase 
motifs (1-4), whereas other members of the MBL superfamily have motif 5 (His263) just after motif 4 (Asp221). 
The crystal structure of TTHA0252 from Thermus thermo-philus HB8, a RNA degradation protein, was the first 
report of the tertiary structure of a β-CASP family protein [86]. TTHA0252 comprises two separate domains: a 
metallo-β-lactamase domain and a "clamp" domain (β-CASP domain) (Fig. 3h). The active site of the enzyme is 
located in a cleft between the two domains, which includes two zinc ions coordinated by seven conserved 
residues. Although this geometry is similar to those of members of the MBL superfamily, TTHA0252 has one 
conserved His residue characteristic of the β-CASP family as a ligand. 
Most eukaryotic messenger RNA precursors (pre-mRNAs) undergo extensive maturational processing, including 
cleavage and polyadenylation at the 3'-end. Recent analyses and the resolution of the 3D structure [87] indicated 
that the 73-kDa subunit of cleavage and polyadenylation specificity factor (CPSF-73) is the endonuclease for this 
and related reactions. CPSF-73 contains two domains, a metallo-β-lactamase domain and a β-CASP domain. 
This second domain can be considered as a cassette inserted into the metallo-β-lactamase domain. The active site 
of CPSF-73, with two zinc ions, is located at the interface of the two domains. The two zinc ions in the active 
site are each bound in an octahedral environment. Zn1 is coordinated by Hisll6, His118 and His196. Zn2 is 
coordinated by Asp120, His121 and motif C (His) of the β-CASP domain. A hydroxide ion and Asp221 are 
bridging ligands (Table 4). CPSF-73 possesses RNA endonuclease activity. Mutations, that disrupt zinc binding 
in the active site, abolish this activity. CPSF-100 shares sequence conservation and a similar domain architecture 
with CPSF-73 but lacks the zinc-binding residues in the metallo-β-lactamase domain. Therefore, CPSF-100 
cannot bind zinc and is unlikely to possess nuclease activity. 
14.        Conclusion 
The metallo-β-lactamase fold clearly represents a stable scaffold that has repeatedly been used during evolution 
to catalyze a diverse range of chemical reactions. Structurally, this diversity is achieved by varying the sequence 
and length of loops near the active site to accommodate various substrates. By combining the metallo-β-
lactamase domain with auxiliary substrate- , product- or cofactor-binding domains, the range of functions has 
been extended yet further. 
The catalytic diversity of this superfamily explains how certain members might have easily evolved into metallo-
β-lactamases in response to environmental antibiotics. The most recent therapeutic utilization of carbapenems 
has subsequently favoured the emergence of preexisting enzymes in pathogenic strains. These data support the 
hypothesis that metallo-β-lactamases may be the result of divergent evolution starting from an ancestral protein 
which did not have a β-lactamase activity. 
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